James Orcutt
Hematology & Oncology · Charleston, SCNPI 1336107424
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 636 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,076 and has fallen 97.7% since, to $70 in 2025.
Across 636 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$894
- AstraZeneca$776
- Merck$774
- Amgen$629
- E.r. Squibb & Sons, L.L.C.$615
- Bristol Myers Squibb$586
- plus $8K from 54 others
Across 37 payments — averaging $28,252 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$727K
- E.r. Squibb & Sons, L.L.C.$173K
- Pfizer$76K
- Merck$45K
- Morphosys AG$12K
- Incyte Corporation$5K
- plus $7K from 2 others
What the payments were for
- Food & beverage$11,77399%
- Education$1361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,909 in reported general payments places this provider in the 75th percentile of 166 hematology & oncology providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 21 | $317,961 |
| CalquenceAcalabrutinib Maleate | 14 | $211,312 |
| EliquisApixaban | 13 | $13,415 |
| Letrozole | 31 | $976 |
| Potassium Chloride | 11 | $255 |
| Acyclovir | 12 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $166 | $317,96121 claims |
| AstraZenecaCalquence | $776 | $211,31214 claims |
| PfizerEliquis | $497 | $13,41513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Charleston
- Ming LimCharleston$94K
- George GeilsCharleston$76K
- Alexander ColtoffCharleston$51K
- Irl GreenwellCharleston$33K
- David EllisonCharleston$33K
- Shelly ShandCharleston$19K
- Nicholas SchmidtCharleston$18K
- George KeoghCharleston$18K
- Brian LingerfeltCharleston$15K
- Robert StuartCharleston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.